IND.227 / KEYNOTE-483
Showed that adding a PD-1 blocker to standard chemotherapy helps in mesothelioma, giving a second immunotherapy-based first-line option.
OS 17.3 vs 16.1 months (HR 0.79); ORR 52% vs 29%. Benefit again concentrated in non-epithelioid disease. FDA approval 17 September 2024 for pembrolizumab with pemetrexed and platinum. An academic-led trial (CCTG) with industry drug supply.
- Median 17.3 vs 16.1 months with Pembrolizumab + chemotherapy compared with Chemotherapy; about 1.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 21 percent lower chance of the event at any given time (hazard ratio 0.79, likely range 0.64 to 0.98).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- 52 vs 29 out of 100 had their tumour shrink with Pembrolizumab + chemotherapy compared with Chemotherapy; 23 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Unresectable pleural mesothelioma, first line: pembrolizumab + platinum-pemetrexed vs platinum-pemetrexed. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
440 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Pembrolizumab + chemotherapy | 222 | 17.3 months | 0.79 (0.64–0.98) | 0.0324 | link |
| Chemotherapy | 218 | 16.1 months | ||||
| Objective response rate | Pembrolizumab + chemotherapy | — | 52% | — | — | — |
| Chemotherapy | — | 29% |
Pages like this
not linked directly; found by shared links- TrialCheckMate 743
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Histology → first-line choice in mesothelioma, Pemetrexed, Mesothelioma.
- TrialBEAT-meso (ETOP 13-18)
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Pemetrexed, Mesothelioma.
- TrialDREAM3R
Shares Pemetrexed, Mesothelioma.
- TrialLUME-Meso
Shares Pemetrexed, Mesothelioma.
- TrialMAPS
Shares Pemetrexed, Mesothelioma.
- TrialSTELLAR
Shares Pemetrexed, Mesothelioma.
- PersonJulie R. Brahmer
Shares Mesothelioma, Pembrolizumab.